Menene Mafi kyawun Maganin rigakafin COVID-19 Ga Masu karɓar Janssen?
Menene Mafi kyawun Maganin rigakafin COVID-19 Ga Masu karɓar Janssen?
Anonim

Yanzu da alluran rigakafin ke yaduwa a cikin kasar, mutane da yawa suna nuna shakku game da samun ƙarin alluran rigakafin da suka bambanta da babban maganin COVID-19 da suke da shi. Wannan gaskiya ne musamman ga waɗanda suka sami rigakafin Johnson & Johnson. Amma akwai shaidar cewa masu karɓar Janssen a zahiri za su amfana da samun ƙarin allurai na Moderna ko Pfizer fiye da wanda J&J da BioNTech ke bayarwa.

Janssen Vs. Moderna da Pfizer Allurar

Kafin zurfafa zurfafa cikin haɗawa da daidaitawar alluran rigakafi da masu haɓakawa, yana da mahimmanci a fara fahimtar bambanci tsakanin rigakafin Janssen da alluran rigakafin daga Pfizer da Moderna. Janssen wani nau'in maganin rigakafi ne mai ɗaukar hoto inda aka kera adenovirus mara lahani don isar da lambar kwayoyin halitta don sunadaran karu waɗanda zasu horar da tsarin garkuwar jiki akan yadda ake amsawa ga ainihin kamuwa da cuta ta SARS-CoV-2.

Ba kamar maganin J&J ba, allurar rigakafin Pfizer da Moderna an rarraba su azaman rigakafin mRNA. Wannan yana nufin cewa sauran alluran rigakafin guda biyu suna isar da lambobin kwayoyin halitta daga kwayar cutar ta SARS-CoV-2 da kanta ga jikin mutum, ta yadda sel za su iya yin kwafin sunadaran karu wanda zai haifar da amsawar rigakafi idan mai karɓa ya fallasa ga ainihin coronavirus, kamar yadda. Yale Medicine ya bayyana.

An tsara maganin alurar rigakafin J&J don zama shiri na nazarin halittu guda ɗaya, yayin da aka yi allurar Moderna da Pfizer don zama shirye-shiryen kashi biyu. Saboda nau'o'insu daban-daban, alluran rigakafi guda uku da ake da su a cikin kasar ma suna da tasiri daban-daban. Rahoton kwatankwacin da Cibiyar Kula da Cututtuka da Cututtuka (CDC) ta fitar a watan Satumba ya nuna cewa rigakafin na Moderna ya ba da kariya kashi 93% ga manya ba tare da wani yanayi ba, yayin da Pfizer ya rubuta 88% kuma Janssen ya ruwaito 71%.

Tasirin Janssen Booster

A cikin Oktoba, Hukumar Abinci da Magunguna ta Amurka ta ba da tallafin rigakafin J&J bisa hukuma don amfanin gaggawa. Wannan yana nufin waɗanda suka sami alluran rigakafin su na Janssen aƙalla watanni biyu da suka gabata yanzu za su iya samun kashi na biyu wanda ake tsammanin zai haɓaka kariyar rigakafin su daga sabon coronavirus a cikin barkewar cutar.

Kafin ba da izini, J&J ya ba da sanarwa yana mai cewa dangane da gwajin asibiti, kashi na biyu na Janssen yana ƙarfafa kariya daga COVID-19. Daga bayanan da aka tattara a yayin gwajin, kamfanin harhada magunguna ya gano cewa mai haɓakawa ya ba da kariya 100% daga kamuwa da cuta mai tsanani da kuma 95% daga kamuwa da alamun bayyanar cututtuka a cikin masu karɓar Amurka. Hakanan an ba da rahoton cewa mai haɓaka Janssen ya samar da matakan rigakafi sau huɗu zuwa shida fiye da babban adadin idan tazara tsakanin su biyu ta kasance aƙalla watanni biyu. A gefe guda, an sami karuwa sau 12 a cikin ƙwayoyin rigakafi idan tazarar ta kasance a cikin watanni shida.

Haɗawa da Daidaita Masu Tallafin Alurar rigakafi

FDA da CDC kwanan nan sun ba da shawarar haɗawa da daidaita allurai masu haɓakawa tsakanin samfuran ukun. Abin da wannan ke nufi shi ne waɗanda suka sami allurar Pfizer za su iya samun abin ƙarfafawa daga Moderna da J&J idan na Pfizer bai isa gare su ba. Hakanan gaskiya ne ga sauran samfuran biyu. Amma idan aka yi la’akari da bambance-bambancen da ake samu a cikin hanyoyin rigakafin, da yawa suna shakku game da samun wani abin ƙarfafawa daban daga babban maganin su.

Masana sun bayyana ra'ayoyinsu game da batun, kuma yawancinsu sun ce masu karbar Janssen za su iya amfana sosai idan za su sami karfin su daga Moderna ko Pfizer. Daga cikin su akwai Donald Alcendor, PhD, mataimakin farfesa a fannin ilimin halittu na Cancer a Kwalejin Kiwon Lafiyar Meharry kuma mataimakin farfesa a fannin ilimin cutar daji a Makarantar Magunguna ta Jami'ar Vanderbilt.

"Shaidu sun kuma nuna cewa akwai karin martanin rigakafin rigakafi yayin da kashi na biyu na allurar rigakafin J&J guda daya shine Moderna ko Pfizer-BioNTech. Wannan yana ba da ɗimbin shaidun shaida waɗanda ke goyan bayan ra'ayin cewa haɗawa da daidaita alurar rigakafin J&J yana da garanti saboda ƙarfin amsawar rigakafin da Pfizer ko rigakafin zamani ya haifar a matsayin kashi na biyu zuwa kashi ɗaya na J&J, "Alcendor ya gaya wa Contagion.

Wani bincike da aka buga a cikin medRxiv a watan da ya gabata ya tantance bambancin inganci tsakanin alluran rigakafi na homologous da heterologous ta hanyar amfani da alamun rigakafin guda uku. Don maganin alurar riga kafi (alurar rigakafi iri ɗaya da ƙarfafawa), sakamakon neutralizing antibody titers ya karu sau 4.2-20. A gefe guda, don allurar rigakafi daban-daban (alurar rigakafi daban-daban da ƙarfafawa), masu ƙima sun karu sau 6.2-76. Sakamakon binciken ya nuna cewa samun ƙarfafawa daban-daban ga masu karɓar Janssen zai haifar da sakamako mai kyau.

"Na ga bayanan, kuma ina fata (FDA) da CDC suma sun gamsu da bayanan. A bayyane yake, idan kun karɓi maganin J&J sannan kuma kun karɓi ɗaya daga cikin allurar rigakafin mRNA, kuna samun babban haɓakawa a cikin rigakafin ƙwayoyin cuta-har ma da ƙarin rigakafi fiye da idan kun sami kashi na biyu na J&J,”Farfesa na Cibiyar Kiwon Lafiya ta Jami'ar Vanderbilt. Medicine William Schaffner, MD, wanda bai shiga cikin binciken ba, ya ce.

Shahararren taken